2 buy-rated ASX growth shares for investors this week

ResMed Inc. (ASX:RMD) and these ASX growth shares could be top options for investors this week. Here's what you need to know about them…

If you're a growth investor, then you're in luck. The local share market is home to a number of top companies that have the potential to grow strongly in the future.

Two top ASX growth shares that have been tipped as buys are listed below. Here's why they are highly rated:

Monadelphous share price rio tinto A small rocket take off from a laptop, indicating a share price surge

Image source: Getty Images

IDP Education Ltd (ASX: IEL)

IDP Education is a provider of international student placement and English language testing services. While it has been hit hard by the pandemic, it has been tipped to come out of the crisis in an even stronger market position. This could make it a big winner when trading conditions return to normal. Particularly given its investment in software, which appears to have given it another edge over the competition.

Last week analysts at Morgans put an add rating and $28.48 price target on the company's shares. While the broker acknowledges that the awful COVID-19 outbreak in India is a headwind, it still believes the risk is to the upside for its earnings. This is due to pent-up demand and marger and acquisition opportunities.

ResMed Inc. (ASX: RMD)

Another growth share to look at is ResMed. This sleep treatment-focused medical device company has been growing at a solid rate for a decade. And thanks to its industry-leading products, growing software business, and the increasing awareness of sleep disorders, it looks well-placed to continue this trend over the next 10 years.

Particularly given its long runway for growth. Management estimates that there are ~1 billion people suffering from sleep apnoea worldwide, with only ~20% of these sufferers currently diagnosed. ResMed also appears well-placed to benefit from the shift to home healthcare thanks to its investments in the space.

Credit Suisse is a fan of ResMed. It recently put an outperform rating and $29.00 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

Red buy button on an Apple keyboard with a finger on it.
Growth Shares

2 ASX shares highly recommended to buy: Experts

Experts are loving the excitement of these stocks.

Read more »

Hour glass next to pile of coins and notes.
Growth Shares

2 top ASX shares to buy and hold for the next decade

These investments have very exciting futures.

Read more »

a graph indicating escalating results
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

I think this is a great time to invest in this stock…

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Growth Shares

A leading fund just bought these top ASX 200 shares

These stocks could be top buys today…

Read more »

Man with hand to his forehead looking at his laptop.
Growth Shares

Droneshield vs Zip Co: Which tech share is the better ASX growth pick?

I unpack Droneshield vs Zip shares to reveal which ASX tech stock looks better for growth-focused investors right now.

Read more »

Piles of increasing coins alongside an hourglass.
Growth Shares

Why I just invested $1,500 into this top ASX growth share

I’m bullish on the future of this ASX growth share…

Read more »

Woman looking at data on her laptop.
Growth Shares

3 ASX 200 shares I would buy and hold for 10 years

These three businesses have the sort of growth runways I want for a 10-year investment.

Read more »

Coins in ascending order from left to right, with a piggy bank and clock on the sides.
Growth Shares

2 top ASX shares to buy and hold for the next decade

These two investments have incredible long-term outlooks.

Read more »